Rhythm Pharmaceuticals (RYTM) Fundamentals 2026 — Revenue Analysis | SniperIQ
Rhythm Pharmaceuticals (RYTM) is a US-listed Healthcare company in Biotechnology with a market capitalization of $7.1B, trading at
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Rhythm Pharmaceuticals's market cap?
Rhythm Pharmaceuticals (RYTM) has a market capitalization of approximately $7.1B, trading at
What is Rhythm Pharmaceuticals's P/E ratio?
Rhythm Pharmaceuticals's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 57.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals runs a net profit margin of -93.3%, a gross margin of 89.4%, and an operating margin of -90.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Rhythm Pharmaceuticals generate?
Rhythm Pharmaceuticals reported revenue of
Does Rhythm Pharmaceuticals pay a dividend?
Rhythm Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Rhythm Pharmaceuticals financially healthy?
Rhythm Pharmaceuticals carries a debt-to-equity ratio of 1.85x and a current ratio of 4.17x, with a market beta of 1.88. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Rhythm Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Rhythm Pharmaceuticals (RYTM) the key facts are: market cap $7.1B, revenue
Track Rhythm Pharmaceuticals's full fundamentals live
Get Rhythm Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.